How is VSTA going to fund the Phase 2 study? Didn't they just terminate engagement of a specialist biotech investment banker and withdrew S-1 filing. That indicates they've been knocking on many doors of knowledgeable pharma investors and came out empty handed. Is Platinum the only funder now -- they don't have much favorable track record on their pharma investments, do they?
Of course, a new anti-depressant drug would be huge -- look at what Lexapro did for Forest Labs.
News 
Market Data 
Discover 
